Spots Global Cancer Trial Database for sacituzumab govitecan
Every month we try and update this database with for sacituzumab govitecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Sacituzumab govitEcan in THYroid Cancers | NCT06235216 | Differentiated ... Anaplastic Thyr... | Sacituzumab gov... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma | NCT06123468 | Esophagogastric... | Sacituzumab gov... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | NCT04434040 | Breast Cancer Triple Negative... Residual Cancer Circulating Tum... | Atezolizumab Sacituzumab gov... | 18 Years - | Dana-Farber Cancer Institute | |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | NCT03337698 | Carcinoma, Non-... | Atezolizumab Cobimetinib RO6958688 Docetaxel CPI-444 Pemetrexed Carboplatin Gemcitabine Linagliptin Tocilizumab Ipatasertib Bevacizumab Sacituzumab Gov... Radiation Evolocumab Tiragolumab XL092 Camonsertib | 18 Years - | Hoffmann-La Roche | |
| Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy | NCT03725761 | Prostate Cancer | Sacituzumab Gov... | 18 Years - | University of Wisconsin, Madison | |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | NCT04595565 | HER2-negative B... Triple Negative... | Capecitabine Carboplatin Cisplatin Sacituzumab gov... | 18 Years - 99 Years | German Breast Group | |
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | NCT06178588 | Locally Advance... Metastatic Chol... Recurrent Chola... Stage III Hilar... Stage III Intra... Stage IV Hilar ... Stage IV Intrah... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Positron Emissi... Sacituzumab Gov... | 18 Years - | University of Kansas Medical Center | |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | NCT06081244 | Triple Negative... | Sacituzumab gov... Pembrolizumab | 18 Years - | West German Study Group | |
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer | NCT06161532 | Small Cell Carc... Small Cell Carc... Squamous Cell C... Squamous Cell C... Primary Adenoca... Primary Adenoca... Renal Medullary... Squamous Cell C... | Sacituzumab gov... Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Strata PATH™ (Precision Indications for Approved Therapies) | NCT05097599 | Cancer Advanced Solid ... | lorlatinib encorafenib + b... talazoparib sacituzumab gov... axitinib | 18 Years - | Strata Oncology | |
| Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | NCT04039230 | Breast Cancer | Talazoparib Sacituzumab Gov... | 18 Years - | Massachusetts General Hospital | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | NCT06328387 | Advanced Breast... Metastatic Brea... | Hydroxychloroqu... Sacituzumab Gov... Trastuzumab Der... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients | NCT06028932 | Ovarian Carcino... | Sacituzumab gov... | 18 Years - | Yale University | |
| HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan | NCT06236269 | Breast Cancer S... | Sacituzumab Gov... | 18 Years - | SOLTI Breast Cancer Research Group | |
| Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer | NCT06356519 | Breast Cancer | Sacituzumab Gov... | 18 Years - 75 Years | Fudan University | |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | NCT03869190 | Urothelial Carc... Bladder Cancer | Atezolizumab Enfortumab Vedo... Niraparib Magrolimab (Hu5... Tiragolumab Sacituzumab Gov... Tocilizumab Cisplatin Gemcitabine | 18 Years - | Hoffmann-La Roche | |
| Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy | NCT05770531 | Metastatic HER2... Metastatic Trip... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Biospecimen Col... Sacituzumab Gov... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | NCT05552001 | Triple Negative... Metastatic Brea... | Sacituzumab gov... | 18 Years - | UNICANCER | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer | NCT05838521 | Cervical Cancer | Sacituzumab gov... | 18 Years - | Yale University | |
| Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers | NCT05884320 | Gland Salivary Gland ... | Sacituzumab Gov... | 18 Years - | M.D. Anderson Cancer Center | |
| Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | NCT03995706 | Glioblastoma | Sacituzumab Gov... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer | NCT06133517 | Urothelial Blad... | Sacituzumab gov... Zimberelimab Domvanalimab | 18 Years - | Fundación para el Progreso de la Oncología en Cantabria | |
| Sacituzumab govitEcan in THYroid Cancers | NCT06235216 | Differentiated ... Anaplastic Thyr... | Sacituzumab gov... | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Sacituzumab Govitecan in Recurrent Glioblastoma | NCT04559230 | Glioblastoma | Sacituzumab Gov... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma | NCT06329869 | Esophageal Squa... | Sacituzumab gov... | 18 Years - | National Taiwan University Hospital | |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | NCT06081244 | Triple Negative... | Sacituzumab gov... Pembrolizumab | 18 Years - | West German Study Group | |
| Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | NCT05609968 | Carcinoma, Non-... | Sacituzumab Gov... Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan | NCT06236269 | Breast Cancer S... | Sacituzumab Gov... | 18 Years - | SOLTI Breast Cancer Research Group | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | NCT03992131 | Ovarian Cancer Triple-negative... Urothelial Carc... Solid Tumor | Rucaparib Lucitanib Sacituzumab gov... | 18 Years - | pharmaand GmbH | |
| Sacituzumab Govitecan in Recurrent Glioblastoma | NCT04559230 | Glioblastoma | Sacituzumab Gov... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer | NCT06328387 | Advanced Breast... Metastatic Brea... | Hydroxychloroqu... Sacituzumab Gov... Trastuzumab Der... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | NCT05327530 | Locally Advance... | Avelumab Sacituzumab Gov... M6223 NKTR-255 | 18 Years - | EMD Serono | |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | NCT03971409 | Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Invasive Breast... Recurrent Breas... Triple-Negative... Unresectable Br... | Anti-OX40 Antib... Avelumab Binimetinib Utomilumab Liposomal Doxor... Sacituzumab Gov... | 18 Years - | University of California, San Francisco | |
| Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer | NCT05226117 | Urothelial Carc... | Sacituzumab gov... | 18 Years - | IRCCS San Raffaele | |
| Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | NCT05581589 | Muscle Invasive... Stage II Bladde... Stage IIIA Blad... | Lymphadenectomy Radical Cystect... Sacituzumab Gov... | 18 Years - | University of Washington | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | NCT03424005 | Breast Cancer | Capecitabine Atezolizumab Ipatasertib SGN-LIV1A Bevacizumab Chemotherapy (G... Selicrelumab Tocilizumab Nab-Paclitaxel Sacituzumab Gov... Abemaciclib Fulvestrant Ribociclib Inavolisib Inavolisib (9 m... Inavolisib (6 m... Trastuzumab Der... | 18 Years - | Hoffmann-La Roche | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | NCT06167317 | Advanced Solid ... | GS-0201 Sacituzumab Gov... | 18 Years - | Gilead Sciences | |
| Sacituzumab Govitecan In TNBC | NCT04230109 | Invasive Breast... Triple Negative... ER-Negative Bre... PR-Negative Bre... HER2-negative B... | Sacituzumab Gov... Pembrolizumab | 18 Years - | Massachusetts General Hospital | |
| Organoid-based Functional Precision Therapy for Advanced Breast Cancer | NCT06102824 | HER2-negative B... Advanced Breast... | Organoid-guided... Taxane Capecitabine Gemcitabine Vinorelbine Eribulin Anthracycline Carboplatin Utidelone Trastuzumab der... Sacituzumab gov... | 18 Years - 80 Years | Guangdong Provincial People's Hospital | |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | NCT06409390 | Metastatic Brea... | Taxotere Cytoxan Trastuzumab der... Sacituzumab gov... Xeloda Fulvestrant Ribociclib Abemaciclib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | NCT06100874 | Her 2 Positive ... Breast Cancer F... Breast Cancer M... | Sacituzumab Gov... Trastuzumab Trastuzumab and... | 18 Years - | Dana-Farber Cancer Institute | |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | NCT04794699 | Solid Tumor | IDE397 Docetaxel Paclitaxel Sacituzumab gov... | 18 Years - | IDEAYA Biosciences | |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | NCT04434040 | Breast Cancer Triple Negative... Residual Cancer Circulating Tum... | Atezolizumab Sacituzumab gov... | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer | NCT05552001 | Triple Negative... Metastatic Brea... | Sacituzumab gov... | 18 Years - | UNICANCER | |
| Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC | NCT06263543 | Breast Cancer Metastatic Brea... Advanced Breast... Hormone-recepto... Human Epidermal... | Sacituzumab gov... | 18 Years - | Baptist Health South Florida | |
| Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | NCT03995706 | Glioblastoma | Sacituzumab Gov... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | NCT04579224 | Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Refractory Blad... Refractory Rena... Refractory Uret... Refractory Uret... Refractory Urot... Stage IV Bladde... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... | Biospecimen Col... Bone Scan Computed Tomogr... Docetaxel Eribulin Mesyla... Gemcitabine Hyd... Magnetic Resona... Paclitaxel Sacituzumab Gov... | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | NCT05675579 | Breast Cancer | Sacituzumab Gov... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer | NCT06055465 | Lung Cancer | Sacituzumab Gov... Pembrolizumab | 18 Years - | Chinese University of Hong Kong | |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | NCT04468061 | Breast Cancer Triple Negative... PD-L1 Negative | Sacituzumab Gov... Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma | NCT06329869 | Esophageal Squa... | Sacituzumab gov... | 18 Years - | National Taiwan University Hospital | |
| Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC | NCT06263543 | Breast Cancer Metastatic Brea... Advanced Breast... Hormone-recepto... Human Epidermal... | Sacituzumab gov... | 18 Years - | Baptist Health South Florida | |
| Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | NCT05581589 | Muscle Invasive... Stage II Bladde... Stage IIIA Blad... | Lymphadenectomy Radical Cystect... Sacituzumab Gov... | 18 Years - | University of Washington | |
| Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients | NCT04863885 | Metastatic Urot... | Ipilimumab Nivolumab Sacituzumab gov... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | NCT04434040 | Breast Cancer Triple Negative... Residual Cancer Circulating Tum... | Atezolizumab Sacituzumab gov... | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
